Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
15. Oktober 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
12. September 2024 16:05 ET
|
Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
29. August 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
06. August 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
31. Juli 2024 16:05 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering to Present at the Jefferies Global Healthcare Conference
29. Mai 2024 16:05 ET
|
Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
07. Mai 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Recognizes Melanoma Awareness Month
06. Mai 2024 16:30 ET
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
09. April 2024 12:00 ET
|
Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27. März 2024 08:00 ET
|
Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations